Datopotamab deruxtecan

From WikiMD's WELLNESSPEDIA

A novel antibody-drug conjugate for cancer treatment

Datopotamab deruxtecan is an investigational antibody-drug conjugate (ADC) designed for the treatment of various types of cancer. It is being developed by Daiichi Sankyo and AstraZeneca. This ADC is composed of a humanized anti-TROP2 monoclonal antibody linked to a topoisomerase I inhibitor payload, known as deruxtecan.

Mechanism of Action[edit]

Datopotamab deruxtecan targets the TROP2 protein, which is overexpressed in many epithelial cancers. The ADC binds to TROP2 on the surface of cancer cells, facilitating internalization of the conjugate. Once inside the cell, the linker is cleaved, releasing the cytotoxic deruxtecan, which inhibits topoisomerase I, leading to DNA damage and cell death.

Development and Clinical Trials[edit]

Datopotamab deruxtecan is currently undergoing clinical trials to evaluate its efficacy and safety in various cancer types, including breast cancer, non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC). Early-phase trials have shown promising results, with significant antitumor activity observed in patients with advanced solid tumors.

Potential Indications[edit]

The primary focus of datopotamab deruxtecan's development is for cancers that express TROP2. These include:

Safety and Side Effects[edit]

As with other ADCs, the safety profile of datopotamab deruxtecan is closely monitored. Common side effects observed in clinical trials include nausea, fatigue, and hematological toxicities. The risk of interstitial lung disease (ILD) is also a concern, as seen with other ADCs containing deruxtecan.

Future Directions[edit]

Ongoing research aims to optimize the use of datopotamab deruxtecan in combination with other therapies, such as immune checkpoint inhibitors and chemotherapy. The goal is to enhance its efficacy and broaden its application across different cancer types.

Related pages[edit]

Diagram of Deruxtecan ADCs

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Datopotamab_deruxtecan&oldid=6430644"